2012 "Restructuring"

Quote

It’s the worse kept secret ever. R&D, QA, QC and a good amount of production will be going to China. There will be skeleton crews in the USA. The reasoning is more about population and growth of the other geo’s than performance. There are 311 million people in the USA and 3 billion in China and India. They will us that to justify the massive move. I hope our pipeline does not take a hit during the transitional period.
 
Anonymous said:
Been through this several times and most layoffs are done by outside organizations. One of the first things considered is the cost of keeping verses the cost of severing. SP reps, by in large, make far less than their Merck counterparts and some have just as much "tenure." But many have less making us targets in the sense they may owe us less to get rid of those with only five or six years. We would certainly be cheaper to keep based on salary and with same tenure. That being said, it is pretty tough to severe a Merck employee with 15 to 20 years because the package would be too expensive especially for the over 50 crowd, better to just let them either raise their hand or wait to retire. Next thing considered is male/female ratios and age/disability. No company can layoff an over abundance of over 50s and not raise a red flag. So, the layoffs have to be fairly even. Territory alignment is then considered on how the areas will be divided and which reps are located close to dead center. If two are fairly equal in age, income, tenure, then they look at performance and tend to keep the rep with the best performance. Many of my SP counterparts received awards and promotions. I think any "failing" division such as Psych will be gone. Mirror overlays will be gone. Hospital IV will be restructured but with smaller territories to prepare for launch of two new IV products. PCP will take the hardest hit and many jobs there will go contract. Managers will have more people to manage. DCOs (sadly) are probably safe but maybe a few lowlifes will be given their walking papers. Let's put it this way, if you have two IV hospital reps, one with seven years making a salary of 87 and one with 15 making a salary of 100, both with the same performance but one has more contacts in the new products' launch and is better aligned and over fifty, they will keep the latter. The cost of the higher salary will balance against that person in severance and that person does not have the call point experience. SP CCG just got EKG books. The new drug is EP. You figure it out.
Click to expand...

" One of the first things considered is the cost of keeping verses the cost of severing." ABSOLUTELY WRONG! and NOT A MAJOR FACTOR, IF AT ALL! THis is just another typical rant, from a typical self entitled, and paranoid rep. I wont think for you, but you should just think about your statement, and its implications. Then you will see how non-nonsensical it is. Now in the absence of logic, if you can suplly us with some absolute referencable proof backing your claim, I will stand corrected.
 
Everyone feels that way. I’m not a big fan for reps. I think they are overpaid wastes of space, but there is not much meat on the bone. They already have done a lot of cutting for overlapping areas. I guess we will see what happens. If that is the reason why, so be it. Investors will be happy.
 
Anonymous said:
" One of the first things considered is the cost of keeping verses the cost of severing." ABSOLUTELY WRONG! and NOT A MAJOR FACTOR, IF AT ALL! THis is just another typical rant, from a typical self entitled, and paranoid rep. I wont think for you, but you should just think about your statement, and its implications. Then you will see how non-nonsensical it is. Now in the absence of logic, if you can suplly us with some absolute referencable proof backing your claim, I will stand corrected.
Click to expand...

What is your answer?

Your response to 134 makes no sense, while they make complete sense.

You are the one who seems very "non-sensical" and illogical.....You are actuallu the one ranting and rambling....ps....no real word, "self-entitled"...maybe you're really the one with the entitlement mentality...and way above any of those typical bleep bleep reps....
 
Anonymous said:
Everyone feels that way. I’m not a big fan for reps. I think they are overpaid wastes of space, but there is not much meat on the bone. They already have done a lot of cutting for overlapping areas. I guess we will see what happens. If that is the reason why, so be it. Investors will be happy.
Click to expand...

everyone feels what way? curious what your position is....do you have a lot of meat on the bone? are you not an overpaid waste of space? what makes anyone a fan of you? bet you are nothing but a piece os sh*t
 
I don't like the way pending layoffs bring out the worst in people. We're all just trying to make a living a support our families. As Tiny Tim said, "God Bless Us, Every One." Good luck to all.
 
Anonymous said:
" One of the first things considered is the cost of keeping verses the cost of severing." ABSOLUTELY WRONG! and NOT A MAJOR FACTOR, IF AT ALL! THis is just another typical rant, from a typical self entitled, and paranoid rep. I wont think for you, but you should just think about your statement, and its implications. Then you will see how non-nonsensical it is. Now in the absence of logic, if you can suplly us with some absolute referencable proof backing your claim, I will stand corrected.
Click to expand...

Ahh, my DCO telling a very tenured Merck rep that raised his/her hand the last time that he/she was NOT given the package because it would have been too expensive to let them go that way. (Pension is a different fund than getting a package.) You are an idiot. Every company considers costs when severing employees. Granted, it gives them a chance to "clean house" of anyone they don't like or who is under performing. But I knew reps out on disability that were kept and some that had horrible numbers, while others with multiple wins were let go. Exactly what criteria do you think an OUTSIDE COMPANY is looking at? Your HR file? Your PMP? Your customer score? Give me a break.
 
Anonymous said:
For some reason I feel the brunt of the layoffs coming up will be limited and heavily tilted toward taking out L-SP reps. How many in your district had a "promotion" from Sr Rep to Exec in last 2 years. How many L-SP reps do you know got any major "award" in the last 2 years. How many L-SP reps do you know have become butt kissers for their CTL? It's the way business works. As L-SP I saw it at SGP when Bayer was purchased they were the red headed step children for SGP. Merck sets a nice legal paper trail to support who needs to be kicked off the island. Your thoughts fellow L-SP reps?
Click to expand...

L-SP here. i think your right. not because the reps are bad reps but merck didnt want the reps in the merger, they let go 85% of SGP. they had to take the 15% of SGP reps because it was part of the merger agreement. SGP reps are not respected by managers, have no ass kissing ability and are productivity producers. merck doesnt like hard working reps that wont kiss ass. they hired contact reps, promoted low producing ass kissers to S3 positions and will lay off almost all SGP based on a company name instead of a persons ability to produce. you shouldnt have to kiss ass when you do a good job! to quote "F U MERCK"
 
Anonymous said:
Any info yet on the content of the EBB taking place 4/30/12? Hard choices?
Click to expand...

Earnings call on 4/27 should let all the cats out of their bags at the very latest. We warned back in Feb that 1Q earnings would be below guidance but kept full year guidance intact. That either means we will be barely off 1Q guidance (doubtful since we made the announcement) OR we expect to have a stellar next 3 quarters (again, doubtful as we lose Singulair) OR they are about to, again, substantially reduce the cost base. If this were Let's Make A Deal I'd be asking Monty for Door #3.
 
Merck is going to buy Amylin for their diabetes products. It will boost Merck's stock and give them a reason for another massive restructuring coming in Fall or first part of next year. (Now, they can focus on cholesterol, cancer and diabetes as well as their vaccine and hospital divisions. IV hospital will be completely restructured/combined with probably a reduction by 20%; Primary care will take the biggest hit with mirror overlays gone.) My guess, is Execs and Leads will be kept and the rest will be gone. There will be handraisers. Amylin will be a bloodbath where just the necessary will be kept and brought into the fold. Good for the shareholders and executive team but more middle class will be out of work. Good luck to you all. It is rough out there if all you have is pharma on your resume. Cannot say more, but it is absolutely coming. CTLs have no idea but the DCOs know for sure.
 
Are you speculating or are you on the inside and know something for sure? I'm ready to leave this place and would love to be a hand-raiser or one of the lucky ones that gets displaced!
 
Anonymous said:
Are you speculating or are you on the inside and know something for sure? I'm ready to leave this place and would love to be a hand-raiser or one of the lucky ones that gets displaced!
Click to expand...

Part of it is speculation, part of it is in the news today. Merck has to do something or it will crash and burn on the stockmarket by next year. Their bid is one of the few being considered right now. I also know that many territories where reps are leaving are not being filled. You figure it out. No budgets, no marketing materials, no presence at conventions, more high pressure tactics to get people to leave, no raises, and less profit = layoffs and restructuring. Let's face it, the SP pipeline has produced shit and probably will. Merck's investment was a complete waste and now they are going to scramble to meet global goals. The only way to do it is to acquire and reduce the headcount again. No other options. You really did not think management is going to get let go did you? hahahahaha

Believe me, unless you've been here a long time, three to six month of severence is not going to get you through to another job, especially if you have spent your life at Merck. That is nearly toxic on your resume.
 
Anonymous said:
Part of it is speculation, part of it is in the news today. Merck has to do something or it will crash and burn on the stockmarket by next year. Their bid is one of the few being considered right now. I also know that many territories where reps are leaving are not being filled. You figure it out. No budgets, no marketing materials, no presence at conventions, more high pressure tactics to get people to leave, no raises, and less profit = layoffs and restructuring. Let's face it, the SP pipeline has produced shit and probably will. Merck's investment was a complete waste and now they are going to scramble to meet global goals. The only way to do it is to acquire and reduce the headcount again. No other options. You really did not think management is going to get let go did you? hahahahaha

Believe me, unless you've been here a long time, three to six month of severence is not going to get you through to another job, especially if you have spent your life at Merck. That is nearly toxic on your resume.
Click to expand...

It is HIGHLY unlikely that Merck is going to be the one to buy this company for several reasons. One being we already have a diabetes franchise, another being we are getting out of the direct R&D game - we just gave the California Institute for Biomedical Research in La Jolla $90 mil to go find something with last month - and, last but most certainly not least, we have warned TWICE that 1Q earnings are not going to make consensus. Amylin turned down $3.5B from BMS so the deal would have to better than that. Try convincing shareholders that missing earnings while spending money on something you supposedly already have (leading class diabetes treatment) and it won't be all sunshine and lollipops.

There are absolutely going to be a bloodbath of layoffs in the next few weeks but it won't be because we are merging with another drug company.
 


Write your reply...
Top Bottom
Back
Quote